- Home
- TWST
as of 03-16-2026 3:58pm EST
Twist Bioscience Corp is a synthetic biology company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's proprietary semiconductor-based manufacturing process synthesizes DNA on silicon rather than traditional plastic plates, enabling the production of high-quality synthetic DNA faster, more affordably, and at scale. This platform overcomes conventional inefficiencies, supports cost-effective, high-throughput synthesis, and allows researchers to accelerate innovation. Geographically, the company operates across the Americas, EMEA, and APAC, deriving the majority of its revenue from the Americas.
| Founded: | 2013 | Country: | United States |
| Employees: | N/A | City: | SOUTH SAN FRANCISCO |
| Market Cap: | 3.0B | IPO Year: | 2018 |
| Target Price: | $48.75 | AVG Volume (30 days): | 1.0M |
| Analyst Decision: | Buy | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.50 | EPS Growth: | 63.89 |
| 52 Week Low/High: | $23.30 - $57.88 | Next Earning Date: | 05-04-2026 |
| Revenue: | $376,572,000 | Revenue Growth: | 20.32% |
| Revenue Growth (this year): | 18.89% | Revenue Growth (next year): | 15.28% |
| P/E Ratio: | -86.64 | Index: | N/A |
| Free Cash Flow: | -75632000.0 | FCF Growth: | N/A |
AI-Powered TWST Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Twist Bioscience Corporation (TWST)
Chief Executive Officer
Avg Cost/Share
$46.43
Shares
2,423
Total Value
$112,490.20
Owned After
860,629
SEC Form 4
SVP of Human Resources
Avg Cost/Share
$46.43
Shares
935
Total Value
$43,408.31
Owned After
124,401
SEC Form 4
See Remarks
Avg Cost/Share
$46.43
Shares
425
Total Value
$19,731.05
Owned After
138,257
SEC Form 4
Chief Accounting Officer
Avg Cost/Share
$46.43
Shares
246
Total Value
$11,420.80
Owned After
54,799
SEC Form 4
Chief Executive Officer
Avg Cost/Share
$46.71
Shares
7,205
Total Value
$336,544.11
Owned After
860,629
SEC Form 4
SVP of Human Resources
Avg Cost/Share
$46.71
Shares
1,465
Total Value
$68,429.86
Owned After
124,401
SEC Form 4
See Remarks
Avg Cost/Share
$46.71
Shares
844
Total Value
$39,423.07
Owned After
138,257
SEC Form 4
Chief Accounting Officer
Avg Cost/Share
$46.71
Shares
1,693
Total Value
$79,079.69
Owned After
54,799
SEC Form 4
President and COO
Avg Cost/Share
$46.71
Shares
4,294
Total Value
$200,571.88
Owned After
284,129
SEC Form 4
Chief Financial Officer
Avg Cost/Share
$46.71
Shares
2,085
Total Value
$97,389.93
Owned After
128,291
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Leproust Emily M. | TWST | Chief Executive Officer | Mar 6, 2026 | Sell | $46.43 | 2,423 | $112,490.20 | 860,629 | |
| Green Paula | TWST | SVP of Human Resources | Mar 6, 2026 | Sell | $46.43 | 935 | $43,408.31 | 124,401 | |
| Cho Dennis | TWST | See Remarks | Mar 6, 2026 | Sell | $46.43 | 425 | $19,731.05 | 138,257 | |
| WERNER ROBERT F. | TWST | Chief Accounting Officer | Mar 6, 2026 | Sell | $46.43 | 246 | $11,420.80 | 54,799 | |
| Leproust Emily M. | TWST | Chief Executive Officer | Feb 23, 2026 | Sell | $46.71 | 7,205 | $336,544.11 | 860,629 | |
| Green Paula | TWST | SVP of Human Resources | Feb 23, 2026 | Sell | $46.71 | 1,465 | $68,429.86 | 124,401 | |
| Cho Dennis | TWST | See Remarks | Feb 23, 2026 | Sell | $46.71 | 844 | $39,423.07 | 138,257 | |
| WERNER ROBERT F. | TWST | Chief Accounting Officer | Feb 23, 2026 | Sell | $46.71 | 1,693 | $79,079.69 | 54,799 | |
| Finn Patrick John | TWST | President and COO | Feb 23, 2026 | Sell | $46.71 | 4,294 | $200,571.88 | 284,129 | |
| Laponis Adam | TWST | Chief Financial Officer | Feb 23, 2026 | Sell | $46.71 | 2,085 | $97,389.93 | 128,291 |
Earnings Transcripts
SEC 8-K filings with transcript text
2025 Q4 Q4 2025 Earnings
8-K BUY Feb 2, 2026 · 100% conf.
Q4 2025 Earnings
8-K BUYFeb 2, 2026 · 100% conf.
1D
+2.23%
$47.94
Act: -1.24%
5D
+7.42%
$50.38
Act: +1.22%
20D
+15.29%
$54.07
Act: -0.53%
twist-20260202FALSE000158128000015812802026-02-022026-02-02
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 2, 2026
Twist Bioscience Corporation (Exact name of registrant as specified in its charter)
Delaware001-3872046-2058888 (State or other jurisdiction of incorporation) (Commission File Number) (I. R. S. Employer Identification No.)
681 Gateway Boulevard South San Francisco, CA 94080 (Address of principal executive offices, including ZIP code)
(800) 719-0671 (Registrant’s telephone number, including area code)
Not Applicable (Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s) Name of each exchange on which registered
Common StockTWSTThe Nasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02Results of Operations and Financial Condition.
On February 2, 2026, Twist Bioscience Corporation (the “Company”) issued a press release announcing its financial results for the quarter ended December 31, 2025. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
The information furnished in this Item 2.02, including Exhibit 99.1, is being furnished and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference into any registration statement or other document filed pursuant to the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.
Item 9.01Financial Statements and Exhibits.
(d)Exhibits.
Exhibit No.Description 99.1Press release dated February 2, 2026 titled “Twist Bioscience Reports Fiscal First Quarter 2026 Financial Results”
104Cover Page Interactive Data File (formatted as Inline XBRL)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: February 2, 2026 Twist Bioscience Corporation
/s/ Judy Yan Judy Yan Assistant General Counsel and Assistant Secretary
2025 Q4 Q4 2025 Earnings
8-K BUY Jan 12, 2026 · 100% conf.
Q4 2025 Earnings
8-K BUYJan 12, 2026 · 100% conf.
1D
+2.23%
$47.94
Act: -1.24%
5D
+7.42%
$50.38
Act: +1.22%
20D
+15.29%
$54.07
Act: -0.53%
twist-20260112FALSE000158128000015812802024-11-182024-11-18
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 12, 2026
Twist Bioscience Corporation (Exact name of registrant as specified in its charter)
Delaware001-3872046-2058888 (State or other jurisdiction of incorporation) (Commission File Number) (I. R. S. Employer Identification No.)
681 Gateway Boulevard South San Francisco, CA 94080 (Address of principal executive offices, including ZIP code)
(800) 719-0671 (Registrant’s telephone number, including area code)
Not Applicable (Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s) Name of each exchange on which registered
Common StockTWSTThe Nasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02Results of Operations and Financial Condition.
On January 12, 2026, Twist Bioscience Corporation (the “Company”) issued a press release announcing its preliminary, unaudited revenue results for the first quarter ended December 31, 2025. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
The Company’s revenue expectations included in this Current Report on Form 8-K are preliminary and unaudited and are subject to change based on the completion of ongoing internal control, review and audit procedures. As a result, these amounts may differ materially from the amounts that will be reflected in the Company’s unaudited condensed financial statements for the fiscal quarter ended December 31, 2025. Accordingly, stockholders should not place undue reliance on this preliminary estimate.
The information furnished in this Item 2.02, including Exhibit 99.1, is being furnished and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference into any registration statement or other document filed pursuant to the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.
Item 9.01Financial Statements and Exhibits.
(d)Exhibits.
Exhibit No.Description 99.1Press release dated January 12, 2026 titled “Twist Bioscience Announces Preliminary First Quarter Fiscal 2026 Revenue”
104Cover Page Interactive Data File (formatted as Inline XBRL)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: January 12, 2026Twist Bioscience Corporation
/s/ Judy Yan Judy Yan Assistant General Counsel and Assistant Secretary
2025 Q3 Q3 2025 Earnings
8-K Nov 14, 2025
Q3 2025 Earnings
8-KNov 14, 2025
twist-20251114FALSE000158128000015812802024-11-182024-11-18
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 14, 2025
Twist Bioscience Corporation (Exact name of registrant as specified in its charter)
Delaware001-3872046-2058888 (State or other jurisdiction of incorporation) (Commission File Number) (I. R. S. Employer Identification No.)
681 Gateway Boulevard South San Francisco, CA 94080 (Address of principal executive offices, including ZIP code)
(800) 719-0671 (Registrant’s telephone number, including area code)
Not Applicable (Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s) Name of each exchange on which registered
Common StockTWSTThe Nasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02Results of Operations and Financial Condition.
On November 14, 2025, Twist Bioscience Corporation (the “Company”) issued a press release announcing its financial results for the fourth quarter and fiscal year ended September 30, 2025. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
The information furnished in this Item 2.02, including Exhibit 99.1, is being furnished and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference into any registration statement or other document filed pursuant to the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.
Item 9.01Financial Statements and Exhibits.
(d)Exhibits.
Exhibit No.Description 99.1Press release dated November 14, 2025 titled “Twist Bioscience Reports Fiscal Fourth Quarter and Full Year Fiscal 2025 Financial Results”
104Cover Page Interactive Data File (formatted as Inline XBRL)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: November 14, 2025Twist Bioscience Corporation
/s/ Judy Yan Judy Yan Assistant General Counsel and Assistant Secretary
Compare TWST vs Leading Stocks
See how TWST stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "TWST Twist Bioscience Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.